Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research note published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $110.00 target price on the stock.

KYMR has been the topic of a number of other reports. Stephens boosted their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Citigroup lifted their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. UBS Group upped their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. B. Riley Financial increased their price objective on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Leerink Partners lifted their price objective on Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $118.90.

Kymera Therapeutics Trading Up 0.7%

NASDAQ:KYMR opened at $79.60 on Monday. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00. The firm has a market capitalization of $6.50 billion, a price-to-earnings ratio of -21.63 and a beta of 2.20. The business’s fifty day moving average price is $79.36 and its 200 day moving average price is $68.77.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company’s revenue was down 60.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.88) EPS. Equities analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Jeremy G. Chadwick sold 25,758 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the transaction, the chief operating officer owned 68,052 shares in the company, valued at approximately $5,668,731.60. This trade represents a 27.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jared Gollob sold 4,895 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the completion of the sale, the insider directly owned 117,134 shares of the company’s stock, valued at approximately $9,991,530.20. The trade was a 4.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 196,561 shares of company stock valued at $17,097,428. 16.01% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP lifted its position in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Kymera Therapeutics in the 3rd quarter valued at approximately $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.